Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.

Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.

Therapeutic methods including administration of cyclosporin to an eye of a mammal in combination with administration of a therapeutically active agent effective for treatment of a cancer to said mammal to treat an ocular condition associated with the use of said therapeutically active agent are disclosed herein.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Provided are: a method of producing a therapeutic agent for skin lesions suitable for treatment or prevention of a skin lesion such as a bedsore; and a therapeutic agent for skin lesions produced by the production method. The method of producing a therapeutic agent for skin lesions characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the therapeutic agent for skin lesions produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzymatically degraded royal jelly, gnetum or its extract, and gnetin C.

Disclosed is a genome stability enhancer comprising, as an active ingredient, at least one member selected from the group consisting of enzymatically degraded royal jelly, gnetum or its extract, and gnetin C.

A pharmaceutical composition for treating leukemia, including by weight 2 to 8% of realgar, 25 to 42% of indigo naturalis, 50 to 60% of salvia miltiorrhiza, and 6 to 10% of heterophylla.

A pharmaceutical composition for treating leukemia, including by weight 2 to 8% of realgar, 25 to 42% of indigo naturalis, 50 to 60% of salvia miltiorrhiza, and 6 to 10% of heterophylla.

The extract of Agathis robusta as an antifungal agent is prepared by hydrodistillation of the powdered bark of A. robusta in a Clevenger-type apparatus at 100 C. for 6 hours to obtain the essential oils of A. robusta. The essential oil is mixed with an ointment base of cholesterol, liquid paraffin, lanolin, and vaseline album, the powdered essential oil of A. robusta being added to the ointment base at 1 or 2% w/w and homogenized to a smooth ointment. When tested in vivo on Wistar rats topically infected with Candida albicans, both the 1% and 2% ointment formulations demonstrated substantial antifungal activity.